In Brief: Urologix/Boston Scientific
This article was originally published in The Gray Sheet
Urologix/Boston Scientific: Enter distribution agreement under which Boston Scientific obtains exclusive right to market Urologix' T3 (Transurethral Thermo-ablation Therapy) system for treatment of benign prostatic hyperplasia in all markets outside the U.S. and Japan. BSC begins exhibiting the T3 system at the British Association of Urological Surgeons meeting the week of June 24 in Edinburgh, Scotland. In the U.S., Urologix plans to submit a premarket approval application later this year for the T3 system. Nihon Kohden holds marketing rights in Japan, where an application for marketing approval already is pending...
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.